Filtern
Erscheinungsjahr
- 2017 (8) (entfernen)
Dokumenttyp
- Vortrag (4)
- Posterpräsentation (3)
- Zeitschriftenartikel (1)
Schlagworte
- Antimicrobial Resistance (4)
- Antimicrobial coatings (3)
- Biofilms (3)
- Phenotypic diversity (3)
- Biozide (2)
- EU-Biozidverordnung (2)
- Metabolism (2)
- Resistenz (2)
- Escherichia coli (1)
- NanoSIMS (1)
Eingeladener Vortrag
- nein (4)
Cell-to-cell variation and specialization in sugar metabolism in clonal bacterial populations
(2017)
While we have good understanding of bacterial metabolism at the population level, we know little about the metabolic behavior of individual cells: do single cells in clonal populations sometimes specialize on different metabolic pathways? Such metabolic specialization could be driven by stochastic gene expression and could provide individual cells with growth benefits of specialization. We measured the degree of phenotypic specialization in two parallel metabolic pathways, the assimilation of glucose and arabinose. We grew Escherichia coli in chemostats, and used isotope-labeled sugars in combination with nanometer-scale secondary ion mass spectrometry and mathematical modeling to quantify sugar assimilation at the single-cell level. We found large variation in metabolic activities between single cells, both in absolute assimilation and in the degree to which individual cells specialize in the assimilation of different sugars. Analysis of transcriptional reporters indicated that this variation was at least partially based on cell-to-cell variation in gene expression. Metabolic differences between cells in clonal populations could potentially reduce metabolic incompatibilities between different pathways, and increase the rate at which parallel reactions can be performed.
Here, we introduce the BEAT-AMR consortium, which is recommended for funding within the 3rd call of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR).
The aim of the consortium is to investigate fundamental mechanisms that shape antimicrobial resistance in biofilms in relation to the surface and then translate those findings into clinical practice. We thereby aim to generate clinical recommendations on the combinatorial use of biomaterials coated with antimicrobials and antibiotics that avoid the occurrence and transmission of nosocomial biofilm infections with bacteria insusceptible to antibiotics. We established a Europe-wide network of experts in biofilm research, antimicrobial resistance, material sciences, and translational medicine that allows us to investigate those aspects in a coherent framework.
Biofilms are structured communities of bacteria found on surfaces that become embedded within a self-produced extracellular polymeric matrix. Bacteria living in biofilms can tolerate much higher antibiotic concentrations compared to planktonic bacteria and survive long enough to evolve antimicrobial resistance (AMR). They form persistent, hard-to-treat infections and exhibit an intrinsic biology that promotes the development and transmission of AMR. The goal of our consortium is to determine how bacteria adapt to antimicrobials during biofilm formation on surfaces coated with antimicrobials, how AMR mutations are acquired and evolve within mature biofilms, and how population dynamics within biofilms affect the transmission of AMR. Our team provides facilities and clinical research governance for experimental and translational medicine. Our synergy of laboratory, clinical and translational research across Europe will ensure the development of novel and successful interventions and therapeutic outcomes.
Here, we introduce the BEAT-AMR consortium, which is recommended for funding within the 3rd call of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). mechanisms that shape antimicrobial resistance in biofilms.
The aim of the consortium is to investigate fundamental in relation to the surface and then translate those findings into clinical practice. We thereby aim to generate clinical recommendations on the combinatorial use of biomaterials coated with antimicrobials and antibiotics that avoid the occurrence and transmission of nosocomial biofilm infections with bacteria insusceptible to antibiotics. We established a Europe-wide network of experts in biofilm research, antimicrobial resistance, material sciences, and translational medicine that allows us to investigate those aspects in a coherent framework.
Biofilms are structured communities of bacteria found on surfaces that become embedded within a self-produced extracellular polymeric matrix. Bacteria living in biofilms can tolerate much higher antibiotic concentrations compared to planktonic bacteria and survive long enough to evolve antimicrobial resistance (AMR). They form persistent, hard-to-treat infections and exhibit an intrinsic biology that promotes the development and transmission of AMR. The goal of our consortium is to determine how bacteria adapt to antimicrobials during biofilm formation on surfaces coated with antimicrobials, how AMR mutations are acquired and evolve within mature biofilms, and how population dynamics within biofilms affect the transmission of AMR. Our team provides facilities and clinical research governance for experimental and translational medicine. Our synergy of laboratory, clinical and translational research across Europe will ensure the development of novel and successful interventions and therapeutic outcomes.
Most microorganisms live in environments where nutrients are limited and fluctuate over time. Cells respond to nutrient fluctuations by sensing and adapting their physiological state. Recent studies suggest phenotypic heterogeneity in isogenic populations as an alternative strategy in fluctuating environments, where a subpopulation of cells express a function that allows growth under conditions that might arise in the future. It is unknown how environmental factors such as nutrient limitation shape phenotypic heterogeneity in metabolism and whether this allows cells to respond to nutrient fluctuations. Here, we show that substrate limitation increases phenotypic heterogeneity in metabolism, and this heterogeneity allows cells to cope with substrate fluctuations. We subjected the N2-fixing bacterium Klebsiella oxytoca to different levels of substrate limitation and substrate shifts, and obtained time-resolved single-cell measurements of metabolic activities using nanometre-scale secondary ion mass spectrometry (NanoSIMS). We found that the level of NH4+ limitation shapes phenotypic heterogeneity in N2 fixation. In turn, the N2 fixation rate of single cells during NH4+ limitation correlates positively with their growth rate after a shift to NH4+ depletion, experimentally demonstrating the benefit of heterogeneity. The results indicate that phenotypic heterogeneity is a general solution to two important ecological challenges - nutrient limitation and fluctuations - that many microorganisms face. Currently, we use NanoSIMS to develop a new approach that defines functionally-relevant, phenotypic biodiversity in microbial systems. In the last part of my presentation, I will highlight why the concept of phenotypic diversity is relevant for the understanding of antimicrobial resistance.
Question: Most microorganisms live in environments where nutrients are limited and fluctuate over time. Cells respond to nutrient fluctuations by sensing and adapting their physiological state. Recent studies suggest phenotypic heterogeneity in isogenic populations as an alternative strategy in fluctuating environments, where a subpopulation of cells express a function that allows growth under conditions that might arise in the future. It is unknown how environmental factors such as nutrient limitation shape phenotypic heterogeneity in metabolism and whether this allows cells to respond to nutrient fluctuations.
Methods: We subjected the N2-fixing bacterium Klebsiella oxytoca to different levels of substrate limitation and substrate shifts, and obtained time-resolved single-cell measurements of metabolic activities using nanometre-scale secondary ion mass spectrometry (NanoSIMS).
Results: We show that substrate limitation increases phenotypic heterogeneity in metabolism, and this
heterogeneity allows cells to cope with substrate fluctuations [1]. We found that the level of NH4+ limitation shapes phenotypic heterogeneity in N2 fixation. In turn, the N2 fixation rate of single cells during NH4+ limitation correlates positively with their growth rate after a shift to NH4+ depletion, experimentally demonstrating the benefit of heterogeneity.
Conclusion: The results indicate that phenotypic heterogeneity is a general solution to two important ecological challenges—nutrient limitation and fluctuations—that many microorganisms face. Currently, we use NanoSIMS to develop a new approach that defines functionally-relevant, phenotypic biodiversity in microbial systems.
Here, we introduce the BEAT-AMR consortium, which is recommended for funding within the 3rd call of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). The aim of the consortium is to investigate fundamental mechanisms that shape antimicrobial resistance in biofilms in relation to the surface and then translate those findings into clinical practice. We thereby aim to generate clinical recommendations on the combinatorial use of biomaterials coated with antimicrobials and antibiotics that avoid the occurrence and transmission of nosocomial biofilm infections with bacteria insusceptible to antibiotics. We established a Europe-wide network of experts in biofilm research, antimicrobial resistance, material sciences, and translational medicine that allows us to investigate those aspects in a coherent framework.
A relatively recent advance in microbiology is the finding that the majority of infections are caused by bacterial biofilms. Biofilms are structured communities of bacteria found on surfaces that become embedded within a self-produced extracellular polymeric matrix. Biofilms can form on tissues or on biomedical surfaces, such as blood catheters or implants, where they act as a reservoir of potential healthcare-associated infection. Bacteria living in biofilms can tolerate much higher antibiotic concentrations compared to planktonic bacteria and survive long enough to evolve antimicrobial resistance (AMR). They form persistent, hard-to-treat infections and exhibit an intrinsic biology that promotes the development and transmission of AMR. The goal of our consortium is to determine how bacteria adapt to antimicrobials during biofilm formation on surfaces coated with antimicrobials, how AMR mutations are acquired and evolve within mature biofilms, and how population dynamics within biofilms affect the transmission of AMR. We address the hypothesis that understanding the contribution of biofilms to AMR acquisition and spread will lead to the development of novel antimicrobial strategies and medical devices that are more effective in preventing biofilm-associated infection and AMR. Our team provides facilities and clinical research governance for experimental and translational medicine. Our synergy of laboratory, clinical and translational research across Europe will ensure the best chance to develop novel and successful interventions and therapeutic outcomes.